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Abstract
Natural killer (NK) cells are an important element in the immune defense against the orthopox family members vaccinia
virus (VV) and ectromelia virus (ECTV). NK cells are regulated through inhibitory and activating signaling receptors, the latter
involving NKG2D and the natural cytotoxicity receptors (NCR), NKp46, NKp44 and NKp30. Here we report that VV infection
results in an upregulation of ligand structures for NKp30 and NKp46 on infected cells, whereas the binding of NKp44 and
NKG2D was not significantly affected. Likewise, infection with ectromelia virus (ECTV), the mousepox agent, enhanced
binding of NKp30 and, to a lesser extent, NKp46. The hemagglutinin (HA) molecules from VV and ECTV, which are known
virulence factors, were identified as novel ligands for NKp30 and NKp46. Using NK cells with selectively silenced NCR
expression and NCR-CD3f reporter cells, we observed that HA present on the surface of VV-infected cells, or in the form of
recombinant soluble protein, was able to block NKp30-triggered activation, whereas it stimulated the activation through
NKp46. The net effect of this complex influence on NK cell activity resulted in a decreased NK lysis susceptibility of infected
cells at late time points of VV infection when HA was expression was pronounced. We conclude that poxviral HA represents
a conserved ligand of NCR, exerting a novel immune escape mechanism through its blocking effect on NKp30-mediated
activation at a late stage of infection.
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Introduction
Vaccinia virus (VV) is an extensively studied, prototypic
member of the Poxviridae family. It is a large virus with a double-
stranded DNA genome of ,200 kbp encoding ,250 genes [1].
VV has a broad cellular tropism and infects almost any cell line in
culture [1]. VV is highly immunogenic and has been successfully
used to vaccinate against smallpox [2]. Vaccinia-derived vectors
have also been extensively used as expression vectors for foreign
genes and as recombinant vaccines [3]. In spite of various immune
evasion mechanisms [4,5], VV and other poxviruses elicit strong
humoral and cellular immune responses [6–10].
Natural killer (NK) cells play an important role in protective
immune responses against VV [6,11,12] and the ectromelia
mousepox virus (ECTV) [13,14]. Interferon(IFN)-c secretion by
NK and non-NK cells appears to be involved in the antiviral effect
[6,14,15]. Type I interferons are essential for the activation of NK
cells against VV [16,17]. Recently, it has been reported that VV
infection induces ligands for the activating natural cytotoxicity
receptors (NCR), NKp46, NKp44 and NKp30, and increases
susceptibility to lysis by NK cells [18]. VV-induced NCR ligand(s)
were described to appear early during infection but have not been
identified on a molecular level. Furthermore, it was shown that the
activating NK cell receptor NKG2D is involved in the NK-cell
mediated resistance to poxvirus disease in C57BL/6 mice [19].
Expression of NKG2D ligands was reported to be enhanced by
ECTV infection [19].
The functions of NK cells are regulated through a balance of
activating and inhibitory signals, which are transmitted through
particular receptors binding cytokines or ligand structures on
interacting target cells and pathogens [20,21]. Most inhibitory
receptors recognize particular MHC class I isoforms and thereby
ensure tolerance of NK cells against self antigens [22]. CD16,
NKG2D, the natural cytotoxicity receptors (NCR) NKp30,
NKp44 and NKp46, as well as NKp80, DNAM-1, and various
costimulatory receptors are involved in the activation of human
NK cells [20,21].
NCR are important activating receptors for the anti-tumor and
anti-viral activity of NK cells [20,21,23]. Heparan sulfate
proteoglycans have been described as ligand structures for
NKp46, NKp44 and NKp30 [24–26]. Nuclear factor BAT3,
which is released from tumor cells under stress conditions, and a
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ligands for NKp30 [27,28]. We reported that ligands for NKp30
and NKp44 can be detected on the surface and in intracellular
compartments of several kinds of tumor cells [29]. Several NCR
ligands derived from pathogens have been described. The
hemagglutinin protein of influenza and the hemagglutinin-
neuraminidase of Sendai virus and Newcastle disease virus can
bind to NKp46 and NKp44 and activate NK cells [30–33]. The
pp65 matrix protein of human cytomegalovirus (HCMV) has been
shown to bind NKp30 and inhibit its function [34]. In addition to
VV, human immunodeficiency virus and herpes simplex virus
have also been demonstrated to upregulate the expression of NCR
ligands in infected cells [35,36].
Attenuated VV strains are employed to specifically infect and
destroy carcinoma cells in xenograft mouse models [37,38].
Depending on the route of administration VV elicits strong
immune reactions at the site of infection involving cd-T cells,
macrophages and NK cells [8,11,17,39]. The predominance of
particular cytokines and chemokines acting on NK cells suggests
that tumor regression may, in part, be induced by NK cell
cytotoxicity in cooperation with the viral oncolytic process [40,41].
Therefore, it seemed important to study the direct interaction of
poxvirus-infected tumor cells with NK cells and elucidate
molecular mechanisms involved in this interaction.
Here we have identified the HA molecules from VV and ECTV
as novel viral ligand structures for NKp30 and NKp46. While NK
cell activation through NKp30 was found to be blocked by HA,
NKp46 was triggered by HA. VV-infected tumor cells showed a
decreased lysis susceptibility, suggesting that NK cell inhibition
through HA was a dominant factor.
Results
Poxviral infection induces ligands for NKp30 and NKp46
Using soluble NCR ectodomains fused to the Fc portion of
human IgG1 [33] for immunofluorescence stainings, we observed
that upon infection of the human cancer line HeLa with the
poxviruses, vaccinia virus (VV) or ectromelia virus (ECTV),
surface expression of ligand structures for the NK receptors
NKp30 and NKp46 was strongly induced as compared with
uninfected cells (Figure 1A,B). The efficiency of infection was
assessed using the monoclonal antibody (mAb) VVI-4G9 to VV
HA, which cross-reacted with the closely related, ECTV-derived
HA molecule. NKp30 and NKp46 ligands were more markedly
induced by VV than by ECTV infection. Poxviral infection,
however, only weakly enhanced the surface expression of ligands
for NKp44. Similar results were obtained when infecting other
human carcinoma cell lines such as A549 and PANC-1 or
melanoma lines with VV or ECTV (see below and data not
shown). We also confirmed previous findings [18], that VV
infection induced NKp30 and NKp46 ligand expression in MRC-
5 human fetal lung fibroblasts as well as in primary, human
foreskin fibroblasts (Figure S1), noted, however, that the
permissivity to VV infection as judged by HA expression, and
the upregulation of NKp30/NKp46 ligands was much lower than
in HeLa cells used in the same experiment. The murine lung
tumor line TC-1 was labeled by NKp30-Fc and NKp46-Fc after
VV infection (Figure 1C), too, suggesting that involved ligand
structures were of viral origin rather than being human host cell-
derived proteins.
HA-deficient VV fails to induce NCR ligands
When analyzing VV deletion mutants we observed that deletion
of the HA gene in VV resulted in a complete abrogation of the
NKp30-Fc and NKp46-Fc surface stainings by infected cells
(Figure 2A), indicating that either HA alone represented the ligand
for NKp30 and NKp46, or constituted part of a complex ligand
structure. Reinsertion of the HA genes from VV or ECTV into
this HA-deficient VV mutant rescued the expression of NKp30
and NKp46 ligands in HeLa cells as shown by infection with such
revertant viruses (Figure 2A). The efficiency of infection by the
HA-deficient mutant virus was monitored by EGFP, which was
introduced into the HA locus of VV strain WR, and expression
levels of reinserted HA were monitored using the anti-HA mAb
VVI-4G9. In accordance with the comparatively weaker staining
of ECTV-infected cells (Figure 1B), infection with the
VV(WR):DHA-HA(ECTV)flag revertant virus reconstituted the
staining by NKp30-Fc and NKp46-Fc less efficiently than
VV(WR):DHA-HA(VV)flag, suggesting that HA from VV was
more efficiently bound by soluble NCR than HA from ECTV.
The nonmembrane-bound viral serine protease inhibitor SPI-3 is
associated with HA on the plasma membrane of infected cells [42].
To analyze whether SPI-3 contributed to the ligand structure we
analyzed the staining of HeLa cells infected with DSPI-3 and
DHA/DSPI-3 VV mutants. While the DHA/DSPI-3 double
mutant produced a complete loss of NKp30 and NKp46 staining
similar to the DHA mutant, deletion of SPI-3 alone had no effect
on NCR binding. Thus, SPI-3 does not appear to be part of the
NCR ligand structure. Bimodal stainings for HA, NKp30-Fc and
NKp46-Fc in Figure 2B were likely due to a non-synchronized VV
infection in this experiment resulting in different HA expression
levels in two subpopulations. Staining of VV-infected cells by
NKp44-Fc was reduced to background levels after infection with
HA-deficient VV suggesting that the weak binding of this NCR
was also HA-dependent.
To obtain additional evidence for the involvement of HA in
binding of NKp30 and NKp46, HeLa cells were infected with VV
strain WR in the absence or the presence of the viral replication
inhibitor cytosine arabinoside (AraC). AraC treatment efficiently
reduced expression of the early and late-phase product HA [43],
which was accompanied by a major reduction of the reactivity of
infected cells with NKp30 and NKp46 (Figure 2C). Here we
compared for the first time the canonical long ectodomain of
NKp30 (contained in the 1C7a, b and c isoforms of NKp30) with
the short isoform that lacks 25 amino acids within the Ig-like
domain (contained in the isoforms 1C7d, e and f). NKp30(short)-
Fc showed a weaker reactivity with VV-infected cells than
NKp30(long)-Fc, but also its binding was strongly diminished by
AraC treatment (Figure 2C).
Author Summary
Natural killer (NK) cells, which belong to the innate
immune system, play a critical role in the defence against
viruses. The orthopoxvirus family member vaccinia virus is
not only used for vaccinations of humans, but is also
presently considered as a promising agent for oncolytic
virotherapy of tumors. It is, therefore, of importance to
better understand mechanisms involved in recognition
and lysis of vaccinia virus-infected cells by NK cells. In this
study, we have identified the hemagglutinin molecule
from vaccinia virus and the related mousepox virus as a
novel interaction partner for two activating receptor
molecules on NK cells. As one of these receptors was
blocked by hemagglutinin, vaccinia-infected cells were less
effectively killed by human NK cells than uninfected cells.
Our findings support the use of hemagglutinin-deficient
VV variants for oncolytic therapy.
NK Cell Activity Altered by Vaccinia Hemagglutinin
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As shown in Figure 3A, the preincubation of VV-infected HeLa
cells with an excess of the anti-HA mAb VVI-4G9 fully blocked
the stainings with NKp30-Fc and NKp46-Fc soluble receptors.
Also, the weak binding of NKp44-Fc was cancelled by anti-HA.
The binding of NKG2D-Fc, which was used as a control, was not
affected by preincubation with anti-HA (Figure 3A). In the same
line, preincubation of NKp30-Fc with soluble monomeric HA
ectodomains from VV reduced their reactivity with VV-infected
PANC-1 cells (Figure 3B). This is probably due to complex
formation and saturation of HA binding sites in NKp30-Fc
chimeras preventing subsequent binding to cell-expressed HA.
Furthermore, preincubation of NKp30-Fc with soluble HA-V5-
His6 reduced the staining of HeLa cells stably transfected with the
cellular NKp30 ligand B7-H6 [28] (Figure 3C). This result
suggests that soluble HA bound to NKp30-Fc chimeras and
blocked binding sites for B7-H6 within NKp30 ectodomains.
While VV infection of HeLa/B7-H6 transfectants resulted in an
enhanced labeling with NKp30, the B7-H6 surface expression of
infected cells, which was detected with a novel B7-H6 reactive
mAb, was even slightly reduced (Figure 3C). Untransfected HeLa
cells only weakly reacted with the anti-B7-H6 mAb, and this
staining was not influenced by VV infection (Figure 3B). These
results indicate that poxviral HA and B7-H6 molecules are
independent ligands for NKp30. The nuclear protein BAT3 has
been reported to mediate NKp30 binding after stress-induced
transfer to the cell surface [27]. While we detected a slightly
increased surface staining for BAT3 in VV-infected HeLa cells, the
BAT3 staining of VV:DHA-infected cells was reduced (Figure 3B).
Thus, a potential BAT3-mediated triggering of NKp30 is unlikely
to explain the enhanced cytolytic activity against VV:DHA-
infected cells (see below).
To study NCR binding to poxviral HA independent of other
viral proteins, HeLa cells were stably transfected with HA(VV) and
HA(ECTV) genes (Figure 3D). We observed increased binding of
NKp30-Fc and NKp46-Fc to HA-expressing HeLa cells. The
enhancement of NCR binding was, however, limited, which was
likely due to ,10 times lower cell surface expression levels of
transfected HA as compared with VV-infected cells.
In enzyme-linked immunosorbent assays (ELISA), NKp30-Fc
and NKp46-Fc also reacted with plate-bound VV particles in an
HA-dependent manner but did not recognize HA-deficient VV
particles (Figure S2). Moreover, soluble recombinant HA(VV) and
HA(ECTV) molecules adsorbed to ELISA plates were recognized
Figure 1. Infection with vaccinia (VV) and ectromelia virus (ECTV) induces ligand structures for NKp30 and NKp46. Human HeLa cervix
carcinoma (A, B) and mouse TC-1 lung carcinoma cells (C) were infected with VV strain WR (A, C) and ECTV strain MP-Nu ¨ (B) for 20 h, or left
uninfected. Top row, infected (black lines) and uninfected cells (gray lines) were labeled with the anti-hemagglutinin (HA) mAb VVI-4G9 to control for
the efficiency of infection, or goat anti-mouse Ig-PE secondary antibodies only (light gray, filled) and analyzed by cytofluorometry. 2nd to 4th row,
Infected and uninfected cells were stained as indicated with soluble chimeric receptors consisting of the ectodomains of NKp30, NKp46 or NKp44,
and the Fc portion of human IgG1. Stainings with goat anti-mouse or anti-human IgG-PE secondary antibody controls are shown as filled histograms.
doi:10.1371/journal.ppat.1002195.g001
NK Cell Activity Altered by Vaccinia Hemagglutinin
PLoS Pathogens | www.plospathogens.org 3 August 2011 | Volume 7 | Issue 8 | e1002195Figure 2. Increased binding of NKp30-Fc and NKp46-Fc is dependent on HA expression. (A) HeLa cells were infected for 18 h with wild-
type VV(WR) (black), ECTV (gray), a HA-deletion mutant of VV (pink) as well as with this DHA mutant reconstituted with the HA genes from VV(WR)
(green) and ECTV (orange). Stainings of uninfected cells are shown as filled gray histograms. Infection efficiencies were monitored by staining against
the late-phase viral product HA (top row) or EGFP (second row), which was inserted into the HA locus of the DHA mutant. Infected and uninfected cells
were labelled with NKp30-Fc, NKp46-Fc and NKp44-Fc. (B) Stainings with anti-HA and NCR-Fc chimeras as in A. Cells were infected with wild-type VV
(gray), VV:DSPI-3 (black), VV:DHA (pink), and VV:DHA/DSPI-3 (green) mutant viruses, respectively. (C) Analysis of NCR binding to HeLa cells infected
with VV(WR) for 18 h in the absence (gray lines) or presence (black lines) of 100 mg/ml cytosine arabinoside (AraC). AraC prevents entry into the late
phase of the viral replication cycle. Uninfected (filled curves) and infected cells were reacted with anti-HA, NKp46-Fc, NKp44-Fc, or chimeric receptors
containing the long or the short ectodomain of NKp30 fused to hIgG1-Fc as indicated.
doi:10.1371/journal.ppat.1002195.g002
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with anti-HA. NKp30-Fc consistently labeled plate-bound HA
1.5–2-fold stronger than equal amounts of NKp46-Fc (Figure S2
and data not shown), suggesting that NKp30 had a higher affinity
for HA than NKp46. The ELISA results fully supported the notion
that HA serves as NCR ligand structure.
Role of NCR-linked glycans and glycans expressed on VV-
infected and uninfected cells
An O-linked carbohydrate attached to Thr 225 has been
described to regulate the binding of NKp46 to influenza virus HA
[44]. Moreover, desialylation abolished the binding of NKp46 and
NKp44 ectodomains to Sendai and Newcastle disease virus
hemagglutinin-neuraminidase [30,31,33]. To better understand
molecular mechanisms involved in the recognition of VV-infected
cells by NKp30 and NKp46, we studied the involvement of N- and
O-linked glycans attached to NKp30 and NKp46. After binding to
protein A Sepharose beads, NKp30-Fc and NKp46-Fc proteins
were treated with N-deglycosylating PNGase F, a cocktail of O-
deglycosylating enzymes, or with neuraminidase alone (Figure 4B),
and used for the staining of uninfected and VV-infected HeLa
cells. As shown in Figure 4A, digestion of potential O-glycans in
the membrane-proximal domain of NKp46 [44,45] strongly
reduced the binding of NKp46-Fc to VV-infected and uninfected
HeLa cells. Desialylation and N-deglycosylation only slightly
reduced the staining intensity. By contrast, binding of NKp30 to
VV-infected cells, for which 2 N-glycans but no O-glycan have
been predicted [46], seems to depend on N-glycosylation as the
staining was markedly reduced by PNGase F treatment
(Figure 4A). Treatment with neuraminidase alone, or the O-
deglycosylating enzyme cocktail (containing neuraminidase),
rather had an enhancing effect on NKp30-Fc binding. We
conclude that different types of glycans are involved in HA binding
to NKp46 and NKp30, and that these binding modes differ from
the sialic acid-dependent binding of NKp46 and NKp30 to other
viral ligands as mentioned above.
Natural cytotoxicity receptors have cellular ligands on carcino-
ma and leukemia cells which are, however, expressed in low
quantities on the cell surface of most cell lines. In addition to the
proteinaceous NKp30 ligand, B7-H6, heparan sulfate proteogly-
cans have been implicated in the binding of NKp30, NKp46, and
NKp44 [24-26]. Furthermore, target cell hyaluronan has been
discussed as ligand structure for NKp46 [47]. In order to
investigate the potential contribution of glycan structures to the
formation of cellular versus viral ligands, we enzymatically
deglycosylated the cell surface of uninfected and VV-infected
HeLa cells. Enzymatic treatments of live cells followed by staining
with NCR-Fc chimeras confirmed an important role of proteo-
glycans as well as of N-linked glycans in the formation of cellular
ligands for NKp30, NKp46 and NKp44 (Figure S3). In addition,
O-linked glycans appeared to contribute to cellular ligand
structures recognized by NKp44. After VV infection, however,
digestion of proteoglycans led to an enhanced binding of NKp30
and NKp46. Removal of anionic proteoglycans may have
unmasked counter-receptors for NKp30 and NKp46 to some
extent. O-linked glycans contributed to the enhanced binding of
NKp30 and NKp46 after VV infection since O-deglycosylation
reduced this binding (Figure S3). Together with the results
presented in Figure 4, these findings suggest that glycan/glycan
interactions are involved in the recognition of VV-infected cells,
and in particular of HA, by NKp30 and NKp46, while exact
mechanisms remain to be explored.
Analysis of NKG2D ligands
Previously it has been reported that the expression of ligands for
the activating NK receptor NKG2D was not affected by VV
infection of human fetal foreskin fibroblasts [18]. In this work, we
essentially confirmed this finding by using NKG2D-Fc chimeric
soluble receptors and VV-infected HeLa cells. A detailed analysis
of the NKG2D ligands MICA, MICB, ULBP1, ULBP2, ULBP3,
and ULBP4 revealed, however, previously unnoted differential
down- or upmodulation of these ligands (Figure S4). In contrast to
VV, infection of HeLa with ECTV resulted in clearly reduced
expression levels of the sum of NKG2D ligands as detected by
human NKG2D-Fc (Figure S4), and is thus at variance with a
recent study demonstrating upregulation of NKG2D ligands upon
ECTV infection of mouse cells [19].
VV infection and HA expression modulates NK lysis
susceptibility and cytokine secretion
Next we assessed the functional impact of VV infection on the
susceptibility to lysis by primary NK cells from different donors.
This is a complex issue due to the involvement of several activating
and inhibitory receptors on responding NK cells. A representative
lysis assay shows the lysis of VV(WR)- and VV(WR:DHA)-infected
HeLa cells side by side and after different periods of VV infection
(Figure 5A). HA expression in the course of infection and, in case
of VV:DHA, expression of EGFP were monitored along with the
infection time-dependent binding of NKp30-Fc and NKp46-Fc
(Figure S5A). NK cells from donor #2 expressed higher levels of
NKp30, NKp46 and NKp44, but lower levels of NKG2D, than
NK cells from donor #1 (Figure S5B). This phenotype correlated
with a more efficient lysis of uninfected and VV-infected HeLa
cells by NK cells from donor #2 (Figure 5A, right part). In this, as
well as several other NK cell assays with similar outcome, we
detected differences in the lysis of target cells infected with either
wild-type VV or HA-deficient VV. At late time points of infection
(12 h, 18 h), when HA expression was high (Figure S5A), wild-type
Figure 3. Characterization of HA as ligand for NKp30 and NKp46. (A) VV-infected HeLa cells were stained with anti-HA to monitor infection
efficiency. Uninfected (gray lines) and infected (black lines) were labelled with NKp30-Fc, NKp46-Fc, NKp44-Fc, or NKG2D-Fc without (thick lines) and
after preincubation of infected cells with an excess of anti-HA mAb (thin lines) as indicated. (B, panels 1-2) Uninfected and VV-infected PANC-1 cells
were reacted with anti-HA to monitor infection efficiency, or with NKp30-Fc, which was either left untreated or preincubated with soluble
recombinant HA-His6 ectodomains. (B, panel 3) Uninfected HeLa cells (filled histogram) and HeLa cells infected with either wild-type VV (black line)o r
HA-deficient VV (gray line) were stained with chicken anti-BAT3 antibodies and FITC-conjugated goat anti-chicken-Ig secondary antibodies. (B, panel
4) Uninfected or VV-infected, normal HeLa cells were stained with anti-B7-H6 mAb to show unaltered basal expression of B7-H6 after infection. (C) VV
infection does not upregulate the cellular NKp30 ligand B7-H6. Uninfected (gray lines) and VV-infected (black lines) HeLa/B7-H6 transfectants were
analyzed with anti-HA, anti-B7-H6, and with NKp30-Fc as indicated (panels 1-3). The staining with NKp30-Fc, but not the staining with anti-B7-H6, is
increased by VV infection. (C, panel 4) B7-H6-transfected HeLa cells were VV-infected and stained with NKp30-Fc fusion proteins that were either
untreated (black line) or preincubated with soluble recombinant HA-His6 (gray line). The staining with PE-conjugated anti-hIgG secondary antibodies
is shown as filled histogram. (D) HeLa cells transfected with HA cDNAs derived from VV(WR) (black lines) and ECTV(MP-Nu ¨)( gray lines) were stained
with anti-HA, NKp30-Fc, NKp46-Fc and NKp44-Fc as indicated. HeLa cells transfected with empty pcDNA3.1(+) expression vector were used for control
(filled histograms).
doi:10.1371/journal.ppat.1002195.g003
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uninfected or VV:DHA-infected targets, suggesting that high HA
expression levels had an inhibitory rather than an activating effect
on NK cells. At 6 h post infection with wild-type VV, and at 6 and
12 h post infection with VV:DHA, we observed a slightly
enhanced lysis susceptibility compared with uninfected targets,
suggesting that HA-independent early viral factors promoted lysis
susceptibility. These assumptions were confirmed in experiments
using AraC to block the entry into the late phase of viral
replication. AraC treatment during VV infection diminished HA
Figure 4. Deglycosylation differentially influences the binding of NKp30-Fc and NKp46-Fc. (A) Uninfected HeLa cells and VV(WR)-infected
HeLa cells were stained with anti-HA to monitor infection efficiency. Uninfected (gray lines) and infected (black lines) were labelled with NKp30-Fc (left
column) and NKp46-Fc (right column) fusion proteins, that were N-deglycosylated in vitro using protein N-glycanase F (PNGase) for 16 h, or treated
with a2-3,6,8,8-neuraminidase (NAase) for 1 h, or with a cocktail of O-deglycosylating enzymes (a2-3,6,8,8-neuraminidase, b1,4-galactosidase, endo-a-
N-acetylgalactosaminidase, b1-2,3,4,6-N-acetylglucosaminidase) for 1 h at 37uC, respectively. (B) Western blots of enzymatically deglycosylated
NKp46-Fc and NKp30-Fc fusion proteins that were detected by NKp30- and NKp46-specific mAbs.
doi:10.1371/journal.ppat.1002195.g004
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PLoS Pathogens | www.plospathogens.org 7 August 2011 | Volume 7 | Issue 8 | e1002195Figure 5. Reduced lysis susceptibility of target cells after infection with wild-type VV. (A) Cytotoxicity assay using primary NK cells from
two different donors as effectors and HeLa cells as targets. HeLa cells were either left uninfected or infected with wild-type VV(WR) or HA-deficient
VV(WR) for 6 h, 12 h and 18 h, respectively, and labeled with
51Cr. Different effector-to-target cell (E:T) ratios are shown. HA surface expression of VV-
infected cells, NCR-Fc binding to wild-type VV and VV:DHA infected cells as well as the expression levels of NKp30, NKp46, NKp44 and NKG2D on NK
NK Cell Activity Altered by Vaccinia Hemagglutinin
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resulted in a reduced lysis of HeLa cells by the human cell line
NK-92 and by primary NK cells, infection with VV:DHA or
infection with VV in the presence of AraC enhanced the lysis
susceptibility as compared with uninfected targets (Figure 5B).
To further investigate the potential inhibitory function of
poxviral HA on NK cells, we utilized HeLa and MaMel-8A cells
transfected with either HA(VV) or HA(ECTV) in cytotoxicity
assays with NK-92 or primary NK cells from different donors. As
compared with vector control transfectants, ectopic expression of
HA(VV) or HA(ECTV) by these tumor cell lines (see Figure 3D)
correlated with a reduced kill by NK-92 and primary NK cells
(Figure 5C). In the same line, inclusion of soluble recombinant
HA(VV) in the cytotoxicity assay reduced the lysis of uninfected
and VV-infected HeLa cells (Figure S6A). Conversely, the
preincubation of VV-infected, but not uninfected, HeLa cells
with anti-HA mAb enhanced their lysis by primary NK cells
(Figure S6B). A partial rescue of the lysis susceptibility of VV-
infected targets was achieved when the target cells were pre-
incubated with soluble NKp30-Fc (Figure S6C), but not with
NKp46-Fc (data not shown). Furthermore, a blocking anti-NKp30
mAb added to the assay mixture partially inhibited the lysis of
uninfected or VV:DHA-infected, but not VV-infected targets (data
not shown), suggesting that in the latter case, HA(VV) had
outcompeted antibody binding to NKp30 on NK cells.
In addition, we studied the effect of VV infection on the
secretion of the effector cytokines TNF-a and IFN-c by primary
IL-2 activated NK cells after cocultivation with VV-infected cells.
HeLa stimulator cells were either left uninfected or infected with
wild-type VV(WR) or VV(WR):DHA, respectively, before UV
irradiation to prevent viral spread to responding NK cells.
Coculture of NK cells with UV-irradiated, uninfected HeLa cells
stimulated the secretion of TNF-a into the culture supernatant,
even though they underwent UV-induced apoptosis. VV:DHA-
infected HeLa also enhanced TNF-a production, whereas VV-
infected HeLa cells blocked TNF-a secretion (Figure S7A).
Primary NK cells cultured alone, or cocultured with uninfected
HeLa cells, produced large amounts of IFN-c (Figure S7B).
Coculture with VV:DHA-infected HeLa cells reduced IFN-c
secretion to ,80% and coculture with wild-type VV-infected
HeLa cells to ,30% of these levels. We conclude that HA-
proficient VV is able to inhibit the secretion of effector cytokines
by NK cells.
NCR triggering is differentially affected by HA and VV
infection
We sought to characterize the individual contributions of the
three NCR to lysis of VV-infected targets. To this end, we
transduced the NK cell line NK-92 with lentiviral vectors
encoding shRNAs specific for NKp30, NKp46 and NKp44.
NK-92 cells express significant levels of NKp30, NKp44 and
NKG2D, yet low levels of NKp46 (Figure 6A). The successful
downmodulation of NCR expression in stably shRNA-transduced
NK-92 cells was demonstrated by staining with anti-NCR
antibodies (Figure 6A). In the same way, off-target effects of
shRNA transfection on the expression levels of non-targeted NCR
and NKG2D were excluded. NK-92 lines with silenced NCR
expression were used in cytotoxicity assays with uninfected and
VV-infected HeLa/B7-H6 targets (Figure 6B). Consistent with B7-
H6 being a major cellular ligand for NKp30, we found that knock-
down of NKp30 significantly reduced the lytic capacity against
uninfected HeLa/B7-H6. NKp46-silenced NK-92 exerted a
reduced kill of uninfected HeLa/B7-H6 suggesting that a
NKp46 ligand was expressed by these targets. NKp44 silencing
reduced the lytic activity only slightly. VV infection resulted in a
strongly reduced lysis of HeLa/B7-H6 by untransduced NK-92
(Figure 6B). Silencing of NKp30 partially rescued this reduced lysis
indicating that it was, in part, caused by inhibition through the
NKp30 receptor. By contrast, NKp46 shRNA transfection
abolished the lysis of VV-infected cells suggesting that cytotoxicity
was triggered by NKp46. Also NKp44-silenced NK-92 showed a
reduced kill of VV-infected HeLa/B7-H6 targets as compared
with regular NK-92. VV-infected and uninfected HeLa/
CLECB12 control transfectants as well as BaF3/B7-H6 targets,
which were not sufficiently infectable by VV, showed similar
patterns of lysis susceptibility to NCR-silenced NK-92 effector cells
(Figure 6C).
NKp30, NKp46 and NKp44 have been reported to occur in
molecular complexes facilitating synergistic signaling [48]. This
cross-talk might obscure the functional outcome of individual
interactions in trans between HA and NCR. To selectively study
triggering by NKp30, NKp46 and NKp44 receptors we utilized
LacZ-inducible BWZ.36 NCR-CD3f reporter cells as previously
published by us [33]. Infection of HeLa cells with VV, but not
VV:DHA, blocked the basic stimulation of BWZ.36/NKp30-f
cells by uninfected HeLa cells (Figure 7A). By contrast, VV and, to
a lesser extent, VV:DHA infection stimulated LacZ induction by
BWZ.36/NKp46-f (Figure 7B), while the influence of VV
infection on BWZ.36/NKp44-f reporter cells was minor
(Figure 7A). We also used HeLa cells stably transfected with HA
from VV or ECTV and vector control transfectants as stimulator
cells. HA expression inhibited the activation of NKp30-f and
stimulated the activation of NKp46-f cells, whereas we noted no
significant HA-specific response by NKp44-f cells (Figure 7C). In
another approach, we plate-coated anti-NCR antibodies to
provide for a basic stimulation of BWZ.36/NCR-f reporter cells.
Crude plasma membrane preparations from VV-infected,
VV:DHA-infected and uninfected HeLa cells were added to the
assay wells. As shown in Figure 7D, membranes from VV-infected
cells interfered with the activation of NKp30-f while they acted
cooperatively with anti-NKp46 for the activation of NKp46-f
reporter cells. Membranes from VV:DHA-infected and uninfected
HeLa cells had no effect. Likewise, soluble recombinant HA(VV)-
Fc partially blocked the activation of NKp30-f cells by anti-
NKp30, but enhanced the activation of NKp46-f cells (Figure 7E).
Surface-adsorbed HA(VV)-Fc stimulated NKp46-f, but not
NKp30-f or NKp44-f reporter cells (Figure 7E). An inhibition
by supernatants from VV-infected cells was also seen when HeLa/
B7-H6 cells were used for the activation of NKp30-f reporter cells
cells used in this experiment are shown in Figure S5. (B) Cytotoxicity assay using the NK cell line NK-92 and primary NK cells from two different donors
as effectors. HeLa targets were infected with either wild-type VV(WR) in the absence or presence of 100 mg/ml AraC, or with VV(WR):DHA mutant
virus. HA surface expression and NCR-Fc binding in this experiment is presented in Figure 2C. Different E:T ratios for NK-92/primary NK cells are
shown. (C) Cytotoxicity assay using HeLa vector control, HA(VV) and HA(ECTV) transfectants as targets, and NK-92 as well as primary NK cells (pNK)
from two donors as effectors. The surface expression levels of transfected HA molecules are shown in Figure 3D. In addition, Ma-Mel-8A transiently
transfected with the empty pcDNA3.1(+) expression vector, pcDNA3.1(+)/HA(VV) and pcDNA3.1(+)/HA(ECTV) were used as targets with primary NK
cells from a third donor as effectors. For statistical comparisons of virus-infected/HA-transfected samples versus uninfected/untransfected samples
Student’s t-test (paired, 2-tailed) was used, n.s., not significant *, p,0.05, **, p,0.01, ***, p,0.001.
doi:10.1371/journal.ppat.1002195.g005
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reporter cells demonstrated that HA had an activating effect for
NKp46 whereas it blocked activation through NKp30.
Discussion
Natural killer cells represent an important element in protective
immune responses against vaccinia and mousepox virus. This is
mainly evidenced by mouse models in which NK cells were
depleted by anti-asialo-GM1 antibodies [6,11,13,14,19,49]. Low
NK cell cytotoxicity in humans is associated with an increased
susceptibility towards severe and recurrent herpesgroup virus
infections [50], whereas little is known about the role of human
NK cells in the defense of poxviral infections.
VV infection sensitizes human tumor cell lines and autologous
T cells for NK-mediated lysis in vitro [51]. More recently, it has
been shown that VV-infected human fibroblasts are recognized by
NK cells through the NCR NKp46, NKp44 and NKp30 [18].
VV-induced NCR ligand structures were, however, not identified
in that study. Genetically engineered forms of the highly
immunogenic poxvirus VV have been successfully employed for
vaccinations of humans [3,52]. Moreover, attenuated VV strains
are presently considered for oncolytic virotherapy in humans [41].
Therefore, it is of importance to identify NK cell ligand structures
induced by poxviruses, particularly in the course of VV infection.
In this study we have identified VV hemagglutinin as a novel
virus-encoded ligand for the activating NK cell receptors NKp30
and NKp46. Several lines of evidence presented herein led to this
conclusion; i, the induction of ligand structures on VV-infected
human carcinoma cells, as detected by staining with soluble
recombinant NKp30 and NKp46 receptors, was fully abolished
after deletion of HA in the viral genome and reconstituted after
reinsertion, ii, anti-HA antibodies blocked the enhanced staining
of VV-infected cells by NKp30- and NKp46-Fc, iii, soluble
recombinant HA interfered with the binding of NKp30 to VV-
infected cells, to VV particles, and to its cellular ligand B7-H6; and
iv, HA-transfected cells showed an increased reactivity with
NKp30-Fc and NKp46-Fc. Furthermore, the binding of NKp30
and NKp46 to plate-bound VV, but not VV:DHA particles, as
well as the blocking effects of anti-HA antibodies and soluble
recombinant HA, confirmed the staining of VV-infected cells. In
the same line, infection of HeLa cells with the mouse poxvirus
ECTV resulted in a significant induction of ligands for NKp30
and NKp46. HA(ECTV) reconstituted NKp30 and NKp46
binding either after infection with a VV:DHA:HA(ECTV) virus
revertant (see Figure 2A) or in HeLa cells stably expressing
HA(ECTV) (see Figure 3D). Our results indicate that the HA
molecule from ECTV also serves as a ligand for human NKp30
and NKp46, however, a HA deletion mutant of ECTV still needs
to be investigated. Mouse NK cells express NKp46 [53], but not
NKp30 [54]. It will be interesting to analyze in future studies
whether ECTV-infected cells are recognized by the murine
homologue of NKp46. Furthermore, the possible interactions of
human NKp30 and NKp46 with variola virus HA, whose
extracytoplasmic domain shares ,84% amino acids with vaccinia
HA, will be of interest since variola is able to establish a systemic
infection of immunocompetent human hosts and might thus be
able to overcome a first-line defence by NK cells more readily.
In accordance with a previous study using human fibroblasts for
infection [18], we detected an induction of NKp44-Fc binding
after infection with VV or ECTV (see Figure 1), which was,
however, weak as compared with the staining of infected cells by
NKp30-Fc and NKp46-Fc. This slightly increased binding of
NKp44-Fc was not observed when cells were infected with the
HA-deficient mutants VV:DHA and VV:DHA/DSPI-3. There-
fore, it seems possible that poxviral HA represents a minor ligand
for NKp44 as well. Binding of NKp44-Fc to viral particles in
ELISA and to HA-transfected HeLa cells was, however, negligible.
The latter result may be explained by the comparatively low
expression levels of HA(VV) and HA(ECTV) on the surface of
HA-transfected cells.
In keeping with previous work [18], the entirety of NKG2D
ligands as detected by NKG2D-Fc soluble receptors were not
significantly altered after VV infection. Upon detailed inspection
we noted, however, a differential behavior of the six NKG2D
ligands tested, with ULBP1, ULBP2 and ULBP4 being slightly
upregulated, MICA and ULBP3 unaltered, and MICB slightly
downregulated. Presently, we have no explanation for this
complexity. Here we show that ECTV infection leads to a partial
loss of staining with human NKG2D-Fc which is reflected in a
decreased reactivity of antibodies against MICB, MICA and
ULBP3 with ECTV-infected human cells. This finding contrasts
with a recent report showing enhanced expression of mouse
NKG2D ligands upon ECTV infection of mouse embryo
fibroblasts and enhanced NKG2D-mediated cytotoxicity [19]. It
is unexpected as humans are not the natural host for ECTV.
Recently, the B7-H6 molecule has been identified as cellular
ligand for NKp30 [28]. The B7 family member B7-H6 contains a
membrane-distal IgV-like domain and a membrane-proximal IgC-
like domain. VV(HA) and NKp30 both contain a membrane-distal
IgV-like domain linked to the membrane through a short
glycosylated stalk region [46,55]. HA from ECTV and VV show
92.5% sequence homology within the N-terminal Ig-like domain.
In light of these structural similarities it seems reasonable to
assume that homotypic interactions within IgV-like domains play a
role in the binding of NKp30 to B7-H6 and poxviral HA,
respectively. As no Ig superfamily member has so far been
reported as ligand structure for NKp46, the interaction of NKp46
with poxviral HA remains elusive at present.
Unexpectedly, we observed that after 12–18 hrs of VV
infection, target cells became less susceptible to lysis by polyclonal
NK cells or by the NK cell line NK-92. At early time points of
infection, when HA expression was low or when the late viral
phase was blocked by AraC, the susceptibility of infected HeLa
cells to NK lysis was, however, slightly increased. Regarding these
modulating effects of VV infection, we noted minor differences
among primary NK cells from different donors. Since infection
with the HA-deficient virus did not reduce lysis susceptibility as
compared with uninfected targets, we reasoned that HA, which is
mainly expressed as a late-phase product [43], had an inhibitory
effect on NK cells, whereas some early phase products may exert a
stimulatory effect on NK cells. This infection-time dependent
Figure 6. NKp30, NKp46 and NKp44 are differentially involved in the lysis of VV-infected targets. (A) Cytofluorometric analysis of NK-92
cells after retroviral transduction with vectors expressing shRNAs specifically silencing NKp30, NKp46 or NKp44 expression. PE-conjugated anti-NCR
mAbs as well as an anti-NKG2D-PE mAb were used for the staining of normal and shRNA-transduced NK-92 cells. (B) Cytotoxicity assay using NCR-
silenced and normal NK-92 cells as effectors as indicated. Uninfected and VV-infected HeLa/B7-H6 cells were used as targets. Different E:T ratios are
shown. (C) Cytotoxicity assay using NCR-silenced and normal NK-92 cells as effector cells as indicated. Uninfected and VV-infected HeLa/CLECB12 as
well as uninfected BaF3/B7-H6 cells were used as targets. Statistical comparison of kills with shRNA-transduced versus normal NK-92 cells was done by
Student’s t-test (paired, 2-tailed), *, p,0.05, **, p,0.01.
doi:10.1371/journal.ppat.1002195.g006
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expressing the ectodomains of NKp30, NKp46, NKp44 or CD16, linked to the transmembrane and cytoplasmic domains of mouse CD3f, were used as
indicated. Induction of LacZ expression is analyzed using the colorigenic substrate CPRG in an ELISA reader as absorption at 595 nm. (A) Reporter
cells were cocultured for 18 h with uninfected HeLa cells, or HeLa cells infected with wild-type VV or HA-deficient VV (5610
4 stimulator cells/well).
Uninfected and infected stimulator cells were pretreated with 254 nm UV light. (B) BWZ.36/NKp46-CD3f reporter cells were cocultured for 20 h with
uninfected HeLa cells, or HeLa cells infected with wild-type VV or HA-deficient VV using the indicated numbers of stimulator cells. Uninfected and
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might explain why in a previous report using slightly shorter
periods of VV infection and human foreskin fibroblasts as targets,
an enhanced lysis but no inhibition was noted [18]. This
contention is corroborated by our results (see Figure S1) showing
that, using the same infectious dose and infection time, VV-
infected human fetal lung fibroblasts and particularly human
foreskin fibroblasts expressed much lower levels of HA than HeLa
cells, corresponding to lesser enhancements of the stainings by
NKp30-Fc and NKp46-Fc. In agreement with our results, in the
mentioned study NK lysis was enhanced after infection with the
HA-deficient VV strain IHD-W as compared with its HA-
competent counterpart IHD-J [18,56].
The inhibitory effect of HA on NK lysis was further
substantiated in this study by using i, VV(WR)- and
VV(WR):DHA-infected targets for NK-92 effectors, ii, using
transfectants expressing HA from VV or ECTV, and iii, using
anti-HA antibodies and soluble NKp30-Fc to enhance the lysis of
VV-infected cells (see Figures 5 and S6). The poxviral HA(A56R)
molecule, which has no lectin-binding properties and is not
essential for viral infection [56], is strongly expressed on the
surface of VV-infected cells and in a major proportion of EEV
membranes [57]. Together with the HA-associated SPI-3 serpin
(K2L), HA blocks the entry of superinfecting virus into VV-
infected cells and syncitia formation [58,59]. HA is a proviral
virulence factor as HA-competent virus replicates much more
rapidly in hosts than HA-deficient virus [60,61]. Our herein
reported finding that NK cell-mediated lysis of wild-type VV-
infected and HA-transfected target cells was reduced is consistent
with the higher virulence of HA-proficient VV and constitutes a
novel immune escape mechanism of VV, and possibly other
poxviral family members, during the late phase of infection. Our
data also showed that SPI-3 was not required for the inhibitory
effect of HA (see Figure 2).
Coculture of preactivated primary NK cells with VV-infected,
UV-irradiated tumor cells resulted in a significant reduction of
IFN-c and TNF-a secretion compared to stimulation by
uninfected, UV-irradiated cells. This functional blockade of NK
cytokine secretion was considerably more pronounced in the
presence of HA-competent than HA-deficient VV, suggesting that
HA exerted an inhibitory effect. As the inhibition of cytokine
secretion in vitro may require a direct contact between infected cells
and NK cells, it does not exclude a systemic activation of NK cells
by type I interferons in secondary lymphoid organs or other non-
infected tissues [17], and is therefore not in conflict with protective
NK-mediated IFN-c responses during poxviral infection as
reported earlier [6,14,15].
Using NK-92 effectors with selectively silenced NCR expression
and LacZ-inducible, NCR-CD3f reporter cells we dissected
differential effects of VV infection and HA expression on
NKp30 and NKp46 triggering. Collectively, our results clearly
document an inhibition of NKp30-mediated activation and a
stimulation of NKp46-mediated activation. This was observed
using VV-infected cells as targets for NCR-silenced NK-92, and
also when NCR-CD3f reporter cells were cultured with UV-
inactivated infected cells, membranes or supernatants derived
from infected cells, HA(VV) and HA(ECTV) transfectants, or
soluble recombinant HA, respectively. Presently, we do not
understand how poxviral HA exerts its inhibitory effect on
NKp30-mediated NK activation, regardless of NKp30 being
present in its natural conformation on NK cells or being expressed
as a CD3f-linked dimer in BWZ.36 reporter cells. In preliminary
experiments using primary NK cells, we failed to detect a reduced
CD3f association with NKp30 after interaction with VV-infected
Hela cells. Such a mechanism has been proposed for the inhibitory
effect of HCMV pp65 protein on NK cells activation through
NKp30 [34]. We rather assume that poxviral HA binds to NKp30
in such a way that cis-interactions of NKp30 with itself or other
proteins and thereby induced conformational changes required for
signal transduction may be prevented. Conversely, the interaction
of HA with NKp46 appears to be productive as NKp46-CD3f
reporter cell triggering is stimulated. Because the net effect of NK
cell interaction with VV-infected cells or soluble recombinant HA
appears to be inhibitory, we assume that interaction of HA with
NKp30 functionally dominates the interaction with NKp46.
As cells infected with VV(WR):DHA showed an increased lysis
susceptibility (see Figure 5) we searched for potential HA-
independent activating ligands. The known NKp30 ligand B7-
H6 could be ruled out (see Figure. 3), and we also could not pin-
point MHC class I downregulation as being responsible for
enhanced NK activation (unpublished results). Consistent with
earlier work [62], regulators of complement activation, CD46,
CD55 and CD59, were slightly enhanced after VV and VV:DHA
infection (unpublished results). CD59 might thus play a role for
VV-enhanced, HA-independent NK cell activation [63]. The
surface expression of LFA-1, LFA-3, CD44, CD24, and in
particular of CD62L molecules, was induced after VV and
VV:DHA infection of HeLa cells (unpublished results). The
functional significance of these findings in terms of augmented
NK cell adhesion to VV-infected cells remains open at present.
In summary, the herein presented results characterize poxviral,
and in particular vaccinia viral, hemagglutinin as novel ligand
structures for the natural cytotoxicity receptors NKp30 and
NKp46, with a possible additional involvement of NKp44. While
NCR reporter cells indicated a blockade of NKp30 triggering
through HA and a stimulation of NKp46 triggering, an inhibitory
effect of VV infection on lysis susceptibility of cancer cells became
dominant at late time points of infection when HA expression was
pronounced. In poxvirus oncolytic therapy, NK cell-mediated
cytotoxicity is discussed to play an important role. Our findings
would support the use of HA-deficient VV variants in therapeutic
approaches employing oncolytic poxviruses.
infected stimulator cells were pretreated with UV light. (C) NCR reporter cells were cocultured for 21 h with HeLa cells stably transfected with either
the empty pcDNA3.1(+) expression vector, pcDNA3.1(+)/HA(VV) or pcDNA3.1(+)/HA(ECTV), respectively. For a negative control, BWZ.36/NCR-CD3f
cells were cultured without stimulator cells. (D) NCR reporter cells were cultured for 18 h in 96-wells coated with either anti-NKp30, anti-NKp46 or
anti-NKp44 mAbs alone, or together with UV-irradiated membranes prepared from uninfected HeLa cells, or from HeLa cells after infection with either
wild-type VV or HA-deficient VV. For a negative control, BWZ.36/NCR-CD3f cells were cultured without prior coating of anti-NCR mAbs. (E) NKp30-f
and NKp46-f reporter cells were cultured for 18 h in 96-wells coated solely with anti-NKp30 or anti-NKp46 mAbs, or coated with mAbs together with
recombinant soluble HA(VV)-Fc fusion protein. For stimulation of reporter cells, HA(VV)-Fc was also coated alone, and non-coated wells were used for
a negative control. (F) NKp30-f and, for control, NKp44-f reporter cells were cocultured for 18 h with HeLa/B7-H6 cells in the absence or the presence
of UV-inactivated supernatants from HeLa cells after infection with either wild-type VV(WR) or VV(WR):DHA. All assays were performed in triplicates.
For statistical comparisons of virus-infected versus uninfected samples (A, B), HA-transfected versus untransfected (C), anti-NCR with membranes
versus anti-NCR without membranes (D), anti-NCR with HA-Fc versus anti-NCR without HA-Fc (E), and HeLa/B7-H6 with supernatants versus HeLa/B7-
H6 without supernatants (F) Student’s t-test was used, n.s., not significant *, p,0.05, **, p,0.01, ***, p,0.001.
doi:10.1371/journal.ppat.1002195.g007
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Cell lines
The human cervix carcinoma HeLa, the human pancreatic
adenocarcinoma line PANC-1, the murine mastocytoma line
P815, and the fetal lung fibroblast line MRC-5 were obtained
from the American Type Culture Collection (ATCC). The human
foreskin fibroblast line VH7 has been described [64]. B7-H6::GFP
transduced HeLa and BaF3 cells are described in Supporting
Information Text S1. HeLa/CLECB12 transfectants have been
described [65]. The metastatic melanoma cell line Ma-Mel-8a
[66] was a kind gift from Dr. A. Paschen, Department of
Dermatology, University Clinics Essen. The murine lung carci-
noma line TC-1/A2 [67] was provided by Dr. A. Cid, DKFZ,
Heidelberg. Cell lines were cultured in RPMI-1640 (Invitrogen,
Karlsruhe, Germany) supplemented with 2 mM glutamine and
10% fetal calf serum. NK-92CI [68] is grown in MEM a medium
supplemented with 2 g/l NaHCO3, 12.5% fetal calf serum, 12.5%
horse serum, penicillin/streptomycin, 1% L-glutamine, and
50 mM 2-mercaptoethanol. NK-92CI (hereafter referred to as
NK-92) is a human natural killer tumor cell line that has been
transfected with human IL-2 cDNA and grows independently of
IL-2.
Plasmids and transfections
The hemagglutin genes of VV strain WR and ECTV strain
MP-Nu ¨ were cloned from mRNA of virus-infected cells using
following primers HA(WR)-59: GAGAAAGGTACCAGATCTC-
TAATATGACACGATTACCAATACTTTTG, HA(ECTV)-59:
GAGAAAGGTACCAGATCTTAATATGGCACGATTGTCA-
ATACTTTTG, and HA-39: CTCTCGAGCTCGGATCCG-
ACTTTGTTCTCTGTTTTGTATTTACG, and inserted in
frame with the FLAG epitope in the vector p7.5k-131A-FLAG.
From these plasmids the coding sequences for HA(VV)flag and
HA(ECTV)flag were subcloned in pcDNA3.1(+) (Invitrogen).
2.5610
5 HeLa cells cultured in 6-well plates were transfected
with 4 mg pcDNA3.1(+)/HA(VV)flag, pcDNA3.1(+)/HA(ECTV)-
flag or empty pcDNA3.1(+) vector and 10 ml lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions. After 2
days, cells were selected with geneticin (1 mg/ml in Dulbecco’s
phosphate-buffered saline [DPBS]; Sigma-Aldrich, Taufkirchen,
Germany) and, after cell sorting for high HA expression,
maintained at 0.5 mg/ml geneticin.
The cloning and expression of B7-H6 cDNA is described in
Supplemental Materials and Methods (Text S1).
Preparation of VV stocks
The VV strains Western Reserve (WR), ectromelia virus
(ECTV) strain MP-Nu ¨ (kindly provided by Dr. H. Ellerbrock,
Robert-Koch-Institut, Berlin, Germany) were used. VV(WR) was
parent of the mutants VV(WR):DHA, VV(WR):DHA-HA(VV)flag
and VV(WR):DHA-HA(ECTV)flag (see Construction of VV HA
mutants). Crude stocks of VV and ECTV were prepared from
supernatants of sonicated infected cells. Cell debris were removed
by centrifugation at 1,680 x g for 10 min. To produce purified VV
stocks supernatants of infected cells were subjected to two
additional centrifugation steps (1,680 x g for 10 min), followed
by centrifugation through a sucrose cushion (36% sucrose, 31,000
x g, 90 min). VV titers were determined by a standard plaque
assay using CV-1 cells.
The SPI-3 and HA-deficient VV mutants VV-T7DSPI-3, VV-
T7DA56 and VV-T7DSPI-3/DA56 have been described [58] and
were amplified and purified as described above. Following
infection of HeLa cells, HA and/or SPI-3 deficiency were
confirmed using the HA-specific mAb VVI-4G9 and the SPI-3-
specific mAb 4A11-4A3 (see Antibodies).
Construction of VV HA mutants
The VV HA deletion mutant was cloned by replacing the HA
gene with an EGFP cassette through homologous recombination.
The 59 and 39 flanking regions of the VV HA gene were cloned in
the pUC18 vector using the following primer pairs, WR180-KpnI:
GAGGGTACCCTCGTTCTAATTGTGGGGGACTG / WR-
181ATG-NcoI: CTCGGATCCGTATTGGTAATCGTGCCA-
TGGATTAGTATAAAAAGTG, and WR181-BamHI: GAGG-
GATCCGCGGCCGCATTTTTGACTTACATAAATGTCTG-
GGATAG / WR182-SphI: CTCGCATGCAATACATTCTAA-
TACGGTCCTGTAGTATCTG. An EGFP cassette was cloned
between the flanking regions. For HA deletion, African green
monkey CV-1 cells (ATCC CCL-70) were infected with wild-type
VV (multiplicity of infection [m.o.i.] 0.05) and after 2 h
transfected with the pUC plasmid containing the EGFP gene
between HA flanking regions using the SuperFect transfection
reagent (QIAgen, Hilden, Germany). Infected cells were harvested
2 days later and lysates produced by freezing/thawing. CV-1 cells
were infected with the lysate in limiting dilution. EGFP-expressing
viruses were selected in two rounds of infection. HA deficiency was
confirmed by cytofluorometric analysis using the anti-HA mAb
VVI-4G9.
FLAG epitope-tagged HA genes from VV and ECTV were
reinserted into the thymidine kinase (TK)l o c u so ft h eV V ( W R ) : DHA
mutant. For homologous recombination, p7.5k-HA(WR)flag and
p7.5k-HA(ECTV)flag plasmids containing HA codings sequences
under control of the TK promoter and homologous flanking regions
of the TK gene were used. The recombinant viruses VV(WR):DHA-
HA(WR)flag and VV(WR):DHA-HA(ECTV)flag were selected by
infecting 143 tk
2 cells in the presence of bromodeoxyuridine.
Viral infection of tumor cells
Tumor cells were seeded in 6-well plates at ,1610
6 cells/well.
Adherent cells were washed once in D-PBS and m.o.i. 4 of VV or
ECTV were added in 500 ml RPMI-1640 without FCS for 1–2 h
at 37u in a CO2 incubator. Medium was replaced by 2.5 ml
complete RPMI-1640 medium in incubated at 37uC for up to 20 h
before harvesting in D-PBS/0.05% trypsin/5 mM EDTA or
enzyme-free cell dissociation buffer (Invitrogen). In some exper-
iments, cytosine D-arabinofuranoside (AraC) (Sigma-Aldrich),
which prevents viral DNA replication and synthesis of late-phase
proteins, was present throughout the infection period at 100 mg/
ml.
Soluble recombinant HA and NCR-Fc fusion proteins
The ectodomains of HAfrom VV(WR) and ECTV were amplified
by using the primer pairs HA(WR)-59: GAGAAAGGTACCA-
GATCTCTAATATGACACGATTACCAATACTTTTG / sHA-
(WR)-39: GAGGAATTCCTACAAAGTCCTTGGTTTTATAA-
TTGC and HA(ECTV)-59: GAGAAAGGTACCAGATCTTAA-
TATGGCACGATTGTCAATACTTTTG / sHA(ECTV)-39:G A -
GGAATTCTCTGCAAAGTCTTTAGTACTATACTTACCTAT
andsubclonedinthe vector pGene/V5-His. Fromthese plasmids, the
coding sequences for V5-His6-tagged, soluble HA(VV) and
HA(ECTV) molecules were subcloned in the plasmid pIRES2-EGFP
(BD Biosciences/Clontech, Heidelberg, Germany). To boost gene
expression, a b-globin intron II (derived from plasmid pSG5,
Stratagene, Amsterdam, The Netherlands) was inserted between
the promoter and coding sequences. Supernatants of HEK293T cells
transiently transfected using the SuperFect transfection reagent
(Qiagen) were harvested and recombinant HA(VV)-V5-His6 and
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columns (GE Healthcare). The correct molecular weights of
recombinant proteins were verified by Western blot using a V5
epitope-specific mAb (Invitrogen).
To produce recombinant, Fc-linked HA molecules, the ectodo-
main of VV(WR) (Met1-Val277) was excised out of pIRES2-EGFP/
VV(WR)-V5-His6 and cloned in frame with PCR-amplified cDNA
coding for the Fc portion of mouse IgG2a (E232-K464) (accession
no. BC031470), using a short EcoRI/BamHI-flanked linker se-
quence (GILQPGGS) derived from pBluescript KS II+ (Invitrogen).
The HA-Fc fusion protein was subcloned into the expression vector
pMT2mcs for transient transfection of HEK293T cells and
purification by protein A Sepharose CL-4B (GE Healthcare Life
Sciences, Freiburg, Germany) as described [33,69]. The integrity of
purified HA-Fc was checked on Western blot using peroxidase-
labeled goat anti-mouse IgG/Fc and enhanced chemoluminescence
as described [69].
NCR-Fc fusion proteins were produced in HEK293T cells as
described [26,33]. Using the calcium phosphate transfection method,
293T cells were transiently transfected with NKp46-hIgG1-Fc,
NKp44-hIgG1-Fc, and NKp30-hIgG1-Fc cDNAs [31] subcloned
into the expression vector pMT2+mcs [69]. The ectodomain of the
NKp30isoform1C7d/e/fwithashorterIgC2-likedomain(accession
no. Y14768; DE65–H89/Q90E with regard to the Ig-like, V-set
domain of the long isoform) has been kindly provided by Dr. Ofer
Mandelboim, (Hebrew University, Jerusalem, Israel). The short
NKp30 ectodomain was also Fc-linked and produced in HEK293T
cells. NCR-Fc chimeric proteins were purified using protein A
Sepharose CL-4B (GE Healthcare Life Sciences, Freiburg, Ger-
many). The integrity of purified NCR-Ig fusion proteins was
confirmed by Western blots using peroxidase-labeled goat anti-
human IgG/Fc. Enzymatic N-/O-deglycosylations of NCR fusion
proteins were done after binding to protein A Sepharose beads to
allow for enzyme removal by washing. Deglycosylations were carried
out as described for VV-infected und uninfected cells (Text S1),
except that PBS [pH 6.0] was used as reaction buffer, and PNGase F
digestions were done for 1 or 16 h at 37uC. The integrity of fusion
proteins and molecular weight shifts after deglycosylation were
confirmed by Western blot using mAbs specific for NKp46 and
NKp30 and peroxidase-labeled goat anti-mouse IgG secondary
antibodies.
Antibodies
Monoclonal antibodies (mAbs) to VVI-4G9 to and B2D10 to
VV hemagglutinin were kindly provided by J.W. Hooper
(Virology Division, USAMRIID, Fort Detrick, MD), and H.
Shida (Institute for Genetic Medicine, Hokkaido University,
Sapporo, Japan), respectively. Rabbit polyclonal antibody to
vaccinia virus was from quartett Immunodiagnostika, Berlin,
Germany. The SPI-3 reactive mAb 4A11-4A3 has been described
[70]. Additional antibodies specific for NK and tumor cell surface
proteins and secondary antibodies are described in Supplemental
Materials and Methods (Text S1).
Flow cytometry
For cell surface immunofluorescence stainings, ,0.5610
6 cells
were washed once in ice-cold FACS buffer (D-PBS/2% FCS)
followed by incubation with a saturating amount of the primary
mouse mAb antibody (0.5–1 mg purified antibodies, 100 ml
hybridoma culture supernatants) for 45 min on ice. After 2
washes, cells were incubated with PE-labeled goat anti-mouse Ig
for 20 min on ice. NCR-Fc fusion proteins (1–2 mg per staining)
were complexed with PE-labeled goat anti-human IgG/Fc
(Dianova; 1 ml in 100 ml FACS buffer) for 30 min before addition
to cells for 45 min on ice. Cells were washed twice with 1 ml
FACS buffer and resuspended in 100 ml FACS buffer with 1.3 mg/
ml propidium iodide (Sigma-Aldrich) to label dead cells. Cyto-
fluorometric analyses were done using a FACSCalibur flow
cytometer and CellQuest software (Becton Dickinson, Heidelberg,
Germany). For all FACS stainings, representative examples from
at least 3 repeats with similar results are shown.
Ethics statement
Primary human NK cells were exclusively isolated from buffy
coats, which were purchased from the Institute for Clinical
Transfusion Medicine and Cellular Therapy, Heidelberg, and had
been made anonymous. The Ethics Commission of the University of
Heidelberg permitted the use of buffy coats for research purposes
without an informed consent by the anomymous blood donor.
Human primary NK cells
Human polyclonal NK cells were isolated from buffy coats using
the NK cell negative isolation kit (Dynal/Invitrogen). 95-99% of
the purified NK cells were CD3
2/CD56
+. Cells were grown in
Iscove’s modified Dulbecco’s medium (IMDM, Invitrogen),
supplemented with 10% human serum, penicillin/streptomycin,
100 U/ml IL-2 (National Institutes of Health cytokine repository),
1 mg/ml phytohemagglutinin P (PHA-P) and irradiated JY
lymphoblastoid cells as feeder cells.
shRNA silencing of NCR
For production of lentiviruses expressing NCR-specific shRNAs,
5610
6 HEK293T cells at exponential growth phase (70–80%
confluent) in DMEM/10% FCS medium were transfected in a
150 cm
2 flask by the calcium phosphate precipitation method with
the following plasmids: 30 mg pLKO.1 shRNA plasmid (1 mg/ml),
15 mg packaging plasmid (psPAX2, 1 mg/ml), 6 mgV S V - Ge n v e l o p e
plasmid (pMD2.G, 0.5 mg/ml). To the plasmid mixture, first 1260 ml
H2O and 163 ml2 . 5MC a C l 2, and then 1500 ml2 xH B S( 2 8 0m M
NaCl, 100 mM HEPES, 1.5 mM Na2HPO4 [pH 7.12]) were added
under vortexing and aeration for 30 sec. The DNA precipitate was
added slowly to HEK293T cells. The packaging and envelope
plasmids were purchased from Invitrogen. Human pLKO.1 lentiviral
shRNA target gene sets for NCR1, NCR2 and NCR3 were from
ABgene (Epsom, UK). Clones TRC0000063537, TRC0000063500
and TRC0000063270 yielded the best silencing effects for NKp46,
NKp44 and NKp30, respectively.
24 h after transfection, culture supernatants were collected from
transfected cells and filtered through a 0.22-mm sterile filter. The
medium was replaced and collected again after 48 h. Cell medium
was stored in 3 ml aliquots at 280uC. For spinfection of 0.5610
6
NK-92 cells, 3 ml of lentivirus-containing medium (with 0.5 mg/
ml Polybrene [Sigma-Aldrich]) was used. Transduced cells were
selected with 1 mg/ml puromycin. The transduction efficiency was
assessed by staining with NCR-specific mAbs. Transduced NK-92
cells were selected with 1 mg/ml puromycin.
Chromium release assays
Target cells (0.5610
6) were labeled in 100 ml assay medium
(IMDM with 10% FCS and 1% penicillin/streptomycin) with
100 mCi (3.7 MBq) of sodium chromate [
51Cr] for 1 h at 37uC.
Cells were washed thrice and resuspended at 5610
4 cells/ml in
100 ml assay medium. Effector cells were resuspended in assay
medium (100 ml/well supplemented with 200 U/ml IL-2) and
mixed at different effector to target (E:T) ratios with 5000 labeled
target cells/well in a 96-well V-bottom plate. In some experiments
recombinant soluble V5-His6-tagged HA(VV) or ICOS-L for
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uninfected and VV-infected target cells were preincubated during
the labeling time with the anti-HA mAb VVI-4G9, the irrelevant
mAb MOPC-21, or NKp30-Fc at ,2 mg/well. In these
experiments, primary NK cell effectors were preincubated with
the FccRIII-blocking antibody CLB-FcR gran/1 (2 mg/1.2610
6
effector cells for 20 min). Maximum release was determined by
incubation of target cells in 1% Triton X-100 solution.
Spontaneous
51Cr release was measured by incubating target cells
in the absence of effector cells. All samples were done in triplicates.
Plates were incubated for 4 h at 37uC. Supernatant was harvested
and
51Cr release was measured in a c-counter. The percentage of
cytotoxicity was calculated according to the following formula:
([experimental release – spontaneous release] / [maximum release
– spontaneous release]) x 100. The ratio between maximum and
spontaneous release was at least 3 in all experiments.
CD3freporter cells and LacZ assays
The generation of LacZ-inducible BWZ.36 reporter cells
expressing NKp46-CD3f, NKp44-CD3f, NKp30-CD3f,o r
CD16-CD3f and the procedure of the LacZ assay has been
described [33]. Briefly, HA-transfected or normal HeLa cells were
plated in a 96-well round-bottom plate (1.25–5610
4 cells/well).
Adherent HeLa cells were infected using m.o.i. 4 in 96-well flat-
bottomed cell culture plates and cultured for 20 h in 100 ml
RPMI-1640/10% FCS medium followed by UV inactivation
(254 nm) of viral particles for 10 min. In some experiments,
ELISA plates were coated with 0.5 mg mAbs against NKp30,
NKp46 and NKp44 (from R&D Systems) in 0.05 M carbonate
buffer (pH 9.6) overnight before washing and addition of reporter
cells. In other experiments, ELISA plate wells were coated with
,1 mg of recombinant soluble HA(VV)-Fc alone or in combina-
tion with anti-NCR mAbs. 50 ml culture supernatant from
VV(WR)- or VV(WR):DHA-infected HeLa cells (m.o.i. 4, 20 h),
that had been cleared from cellular debris by centrifugation at
2300 x g for 5 min and inactivated by exposure to 254 nm UV
light for 10 min, was added to adherent HeLa/B7-H6 cells in
triplicate wells. In another approach, crude membranes were
produced from 5610
6 VV-infected and uninfected HeLa cells by
three cycles of freezing in liquid N2 and thawing, followed by
clearing of intact cells and nuclei at 1000 x g for 5 min, and
pelleting of membranes at 16000 x g for 10 min at 4uCi na
microcentrifuge. Crude membranes were resuspended in 250 ml
and 10 ml added to assay wells in triplicates.
Adherent tumor cells were co-cultured with 10
5 NCR-CD3f
reporter cells for 18 h at 37uC. PMA (phorbol 12-myristate 13-
acetate; 5 ng/ml; Sigma-Aldrich) plus ionomycin (0.5 mg/ml;
Merck/Calbiochem, Darmstadt, Germany) was used as positive
control for the LacZ inducibility in reporter cells. The stimulation
of NCR-CD3f cells was determined by addition of LacZ substrate
buffer (9 mM MgCl2, 0.15 mM CPRG, 100 mM 2-ME, 0.125%
Nonidet P-40 in PBS [pH 7.5]) for 4 h at 37uC. The cleaved
CPRG was measured in an ELISA reader with an absorbance at
595 nm with 630 nm as the reference wavelength. The data are
shown as means of triplicate values and s.e.m. from representative
examples of three similar experiments.
Additional experimental methods can be found in Supplemental
Materials and Methods (Text S1).
Supporting Information
Figure S1 Induction of NKp30 and NKp46 ligands on
VV-infected human fibroblasts. Human MRC-5 fetal lung
fibroblasts (A) and human VH7 foreskin fibroblasts (B) were
infected with VV(WR) using m.o.i. 8 for 20 h, or were mock-
infected before harvesting and staining with the indicated NCR-Fc
fusion protein or the anti-HA mAb VVI-4G9 to monitor infection
efficiencies. (C) For comparison, HeLa cells were infected using
the same conditions and also stained with NKp30-Fc, NKp46-Fc
or anti-HA.
(EPS)
Figure S2 NKp30-Fc and NKp46-Fc bind to plate-coated
viral particles and recombinant HA. (A, B) Enzyme-linked
immunoassays using 96-well plates coated with viral particles (VV
strains WR and Lister, HA-deficient VV(WR)), with recombinant
His6-tagged HA ectodomains from VV and ECTV, or with
recombinant ICOS-L as an irrelevant protein. Coated and washed
ELISA plates were reacted with NKp30-Fc, NKp46-Fc and
NKp44-Fc, followed by incubation with goat anti-hIgG horserad-
ish peroxidase(HRP)-conjugated secondary antibodies. The bind-
ing of viral particles was confirmed using the anti-HA mAb VVI-
4G9 and goat anti-mIgG horseradish peroxidase(HRP)-conjugat-
ed secondary antibodies or polyclonal rabbit anti-VV for
VV:DHA particles, respectively. In (A) and (B), some wells were
incubated for 15 min with the anti-HA mAb VVI-4G9 before
addition of NCR-Fc. In (B), NKp30-Fc was also preincubated with
soluble recombinant HA(VV)-V5-His6 proteins before addition to
the virus-coated ELISA plate (’’NKp30-Fc + sVV(HA)‘‘). The lack of
binding of NKp30/NKp46-Fc to VV:DHA particles and the
partial inhibitions observed in the presence of anti-HA or soluble
HA underpin the HA-specific binding. (C) Western blot showing
SDS-PAGE-separated, recombinant V5-His6-tagged HA(VV) and
HA(ECTV) ectodomains, and V5-His6-tagged ICOS-L as a
control protein, reacted with a mAb specific for the V5 epitope.
(EPS)
Figure S3 Analysis of glycan-based NCR ligands on VV-
infected and uninfected cells. Uninfected (A) and VV-
infected (B) HeLa cells were left untreated or treated with a
mixture of heparanase I and III, or with hyaluronidase (left column),
or deglycosylated with protein N-glycanase F for removal of N-
glycans, a cocktail of O-deglycosylating enzymes, or with
neuraminidase alone (right column), as described in Supplemental
Materials and Methods (Text S1). After enzymatic treatment and
washing, cells were immediately stained on ice with NKp30-Fc,
NKp46-Fc or NKp44-Fc fusion proteins complexed with goat
anti-hIgG-PE secondary antibodies. Heparanase I/III and hyal-
uronidase treatment reduced the staining of uninfected cells by the
three NCR, but enhanced the staining of infected cells by NKp30-
Fc and NKp46-Fc. Desialylation caused a strong enhancement of
NKp44 labeling, whereas it had a reducing effect on NKp30-Fc
binding to infected cells. (C) NP-40 lysates of VV-infected HeLa
(’’H‘‘) cells and murine NIH-3T3 (’’3‘‘) cells, were either left
untreated or digested with endoglycosidase H (Endo H), N-
glycosidase F, neuraminidase or O-glycosidase, respectively. The
lysates were separated by SDS-PAGE and a Western blot reacted
with anti-HA mAb VVI-4G9 and peroxidase-conjugated anti-
mIgG antibodies. The dominant, fully glycosylated, long form of
HA (85 kDa) [42] and the Endo H-sensitive, intracellular short
form of HA (68 kDa) are labeled with ’’L‘‘ and ’’S‘‘. The major
HA form contained ,5 N-glycans and ,2 O-glycans as estimated
from respective shifts in molecular weight after enzymatic
deglycosylations. After neuraminidase treatment a minor portion
of anti-HA-reactive molecules from HeLa lysates migrated at an
apparently higher molecular weight (asterisks). These bands
probably represent unseparated aggregates of HA.
(EPS)
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ligand expression. HeLa cells infected for 20 h with VV (black
lines) or ECTV (gray lines) were stained with mAb VVI-4G9 to
monitor HA surface expression, with soluble NKG2D IgG-Fc
fusion protein and with mAbs recognizing the NKG2D ligands
MICA, MICB, ULBP1, ULBP2, ULBP3, or ULBP4, as indicated.
Uninfected controls are shown with filled histograms. Infection
with ECTV, but not VV, caused a downmodulation of the
NKG2D ligands MICA, MICB and ULBP3.
(EPS)
Figure S5 Cytofluorometric analysis of target and
effector cells used in the cytotoxicity assay of Figure 4A.
(A) Infection time-dependent increase of HA surface and
intracellular EGFP expression in HeLa cells infected for 6, 12
and 18 h, respectively, with wild-type VV(WR) or
VV(WR):DHA[EGFP
+] is shown in the top panel. The time-
dependent increase of NKp30-Fc and NKp46-Fc binding to HeLa
cells infected with wild-type VV for 12 and 18 h, but not to cells
infected with VV:DHA, is shown below. (B) Stainings of primary
NK cells from donor 1 (black lines) and donor 2 (gray lines) with PE-
conjugated mAbs against NKG2D, NKp30, NKp46 or NKp44.
The binding of a PE-labeled control antibody (MOPC-21) is
presented as filled histogram.
(EPS)
Figure S6 Inhibition of NK lysis by poxviral HA. (A)
Uninfected or VV-infected HeLa cells were
51Cr-labeled and used
in a cytotoxicity assay with primary NK cells preincubated with
either soluble recombinant HA-V5-His6 derived from VV(WR), or
an irrelevant recombinant protein (ICOSL-V5-His6). Different
E:T ratios are shown. (B) Lysis assay with primary NK cells as
effectors and uninfected or VV-infected HeLa cells which were
preincubated with either an irrelevant mAb (MOPC21) or with
anti-HA mAb VVI-4G9. NK cells were preincubated with an
excess of the blocking anti-CD16 mAb CLB-FcR gran/1 in order
to prevent Fc receptor binding. (C) HeLa transfected either with
the empty pcDNA3.1(+) vector for control, or with pcDNA3.1(+)/
(HA)ECTV, were used in a lysis assay using NK-92 as effector
cells. Where indicated, target cells were preincubated with an
excess of soluble NKp30-Fc. Statistical comparison of samples
with recombinant soluble HA-V5-His6 versus samples with control
protein (A), samples with anti-HA versus samples with control mAb
(B), and samples with NKp30-Fc versus without NKp30-Fc (C)
were done using Student’s t-test (paired, 2-tailed), *, p,0.05, **,
p,0.01, ***, p,0.001.
(EPS)
Figure S7 VV-infected stimulator cells reduce secretion
of IFN-c and TNF-a by primary NK cells. Enzyme-linked
immunoassays for human TNF-a (A) and IFN-c (B) secreted into
the culture medium of primary IL-2-activated NK cells cultivated
together with uninfected HeLa cells, HeLa cells infected with wild-
type VV(WR), or HA-deficient VV(WR), respectively, for 24 h.
Prior to incubation with NK cells, the stimulator cells were treated
with 254 nm UV light to prevent viral spread. For control, NK
cells were also cultured alone. Statistical comparison of infected
versus non-infected HeLa cells was done using Student’s t-test (2-
tailed), n.s., not significant, ***, p,0.001.
(EPS)
Text S1 Supplemental materials and methods.
(DOC)
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